IMPORTANCE Chronic obstructive pulmonary disease (COPD), a manageable respiratory condition, is the third leading cause of death worldwide. Knowing which prescription medications are the most effective in improving health outcomes for people with COPD is essential to maximizing health outcomes.
C hronic obstructive pulmonary disease (COPD) affects 5% to 22% of adults older than 40 years, has a lifetime risk of more than 25%, and is the third leading cause of death worldwide. [1] [2] [3] Medications are a mainstay of COPD management, and knowing which are most effective in real-world practice is essential. Combination therapy consisting of long-acting β-agonists (LABAs) and inhaled corticosteroids (ICSs) has been shown to decrease exacerbations and possibly decrease mortality compared with placebo. 4 -6 However, there are still gaps in what is known about its comparative effectiveness compared with LABAs alone. A recent systematic review of randomized clinical trials (RCTs) found that exacerbation rates, but not hospitalizations or mortality, were lower in patients treated with LABA-ICS combination therapy compared with LABAs alone. 7 However, it included RCTs that predominantly enrolled younger adult men with few comorbidities and it excluded people with asthma and who were taking long-acting anticholinergics (LAAs), a commonly used COPD medication. Thus, its results may not be generalizable to older, frailer COPD patients with asthma or other comorbidities taking other COPD medications in real-world settings.
There are also downsides to treating with LABAs and ICSs. In RCTs, patients receiving these medications have been shown to have an increased risk of pneumonia compared with patients receiving LABAs alone. 7 A systematic review of RCTs has also shown a non-statistically significant increased fracture risk among LABA and ICS users compared with users of LABAs alone. 8 Moreover, the cost of the combination product is usually greater. The large number of patients receiving LABAs and ICSs, at least in some regions, suggests that starting combination medication for people with COPD occurs often without a preceding trial of LABAs alone. 9 Therefore, we conducted an observational study to examine the association of LABA-ICS combination therapy compared with LABAs alone and the composite outcome of mortality and COPD hospitalizations in older COPD patients with naturally occurring comorbidities, including asthma, in realworld conditions. Because confounding by indication is a potential limitation in observational studies, we performed a number of additional sensitivity analyses.
Methods

Study Design and Setting
We conducted a retrospective cohort study of Ontario residents aged 66 years or older using multiple linked population health care databases. Ontario has a diverse, multicultural population of approximately 2 million people aged 65 years or older. Virtually all residents of all ages receive universal access to physician and hospital services, which are recorded in administrative databases, and those aged 65 years or older receive prescription medications from publically funded insurance programs.
Ethics approval was obtained from the Research Ethics Board of Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. A waiver of informed consent was obtained.
Data Sources
Patient demographic and health care records were linked using encrypted health card numbers, which served as unique and anonymous identifiers across databases. The Ontario Registered Persons Database contains basic demographic information including date of death. 10 The Ontario Drug Benefits database contains prescription medication claims for all residents aged 65 years or older. 11 The Canadian Institute of Health Information's Discharge Abstract Database and National Ambulatory Care Reporting System contain detailed information for all admissions to hospitals and emergency departments. The Ontario Health Insurance Plan physician claims database contains information on all outpatient services provided by feefor-service physicians and "shadow billings" for physicians paid under alternate payment plans.
Responses to 4 cycles of the Canadian Community Health Survey, which is a nationally representative cross-sectional survey designed by Statistics Canada, 12 were used to obtain information such as individual-level smoking status.
Study Population
All Ontario residents aged 66 years or older who met a validated case definition of physician-diagnosed COPD using health administrative data (eAppendix in the Supplement) 13 and were new users of LABAs or LABA-ICS combination therapy between September 1, 2003, and March 31, 2011, were included. This COPD definition has been shown to have a positive predictive value of 81% and a negative predictive value of 88.5% in adults 35 years and older, and a positive predictive value of 86% in adults aged 65 years or older compared with clinical evaluation by a physician. 13, 14 New users were individuals who had not filled a prescription for either of these medications or for ICSs alone in the previous year and were studied to minimize bias due to improved outcomes among long-term users who were presumably benefitting from their medication and worse outcomes among patients who, due to problems, required a step up or down in therapy. 14 LABA-ICS combination therapy and LABAs alone were the only medications considered. The initial prescription date was the index date. Individuals who received prescriptions for both medications on the index date, patients who were ineligible for health insurance, and those who had had lung volume reduction surgery or transplantation were excluded.
Baseline Characteristics
A wide variety of baseline characteristics were determined using the health administrative data (eTable 1 in the Supplement).
Neighborhood income quintiles, shown to be a reasonable proxy for socioeconomic status, 15 were determined by linking postal codes to census data. General measures of comorbidity based on diagnostic information from health services use in the 2 years prior to the index date were determined using the Johns Hopkins Adjusted Clinical Group Case-Mix System.
Outcome Measures
The primary outcome was a composite of all-cause mortality and COPD hospitalization (International Statistical Classification of Diseases, Tenth Revision [ICD-10] codes J41-J43). We excluded COPD hospitalizations with acute lower respiratory tract infection (ICD-10 code J44.0) because we wanted to analyze pneumonia separately. A composite outcome was chosen because factors that lead to COPD hospitalization also lead to mortality; however, we also analyzed mortality and COPD hospitalizations as distinct outcomes. Secondary outcomes included hospitalization for pneumonia (ICD-10 codes J10-J18 and J44.0) and hospitalization for fragility fractures of the spine, pelvis, forearm, or hip (ICD-10 codes S32, S52, and S72) likely to result from osteoporosisboth are suggested adverse effects of ICSs. 7, 8 Patients who did not experience an outcome of interest were censored on March 15, 2012.
Statistical Analysis
Propensity score matching was used to compare patients with similar observed characteristics, all of whom were potential candidates for LABAs or LABAs and ICSs. 17 Multivariable logistic regression was used to compute the propensity score for receiving LABAs alone using all the measured baseline characteristics as predictors. Individuals prescribed LABAs were then matched with up to 3 individuals prescribed LABAs and ICSs on the basis of age (±1 year), sex, codiagnosis of asthma, COPD duration, and propensity score (±0.2 SDs). An absolute standardized difference of less than 10% on all covariates was accepted as adequate balance. 18 We used Cox regression analysis to compare outcomes between the groups while accounting for matching by using marginal proportional hazards models. 19 For hospitalization outcomes, censoring on mortality would have been inappropriate because it is a more serious and common outcome. Therefore, we used subdistribution hazard models to account for the competing risk of mortality to avoid bias due to the high mortality rate. 20 All statistical tests were 2-sided with P < .05 defined as the level of statistical significance and were performed using SAS, version 9.1 (SAS Institute Inc).
Additional Analyses
Stratification factors of interest were identified a priori. We stratified by codiagnosis of asthma 21 because those with asthma might benefit more from LABA-ICS combination therapy and those without asthma are not normally considered to be corticosteroid responsive. 22 We stratified by current or baseline use of LAAs, defined by receipt in the previous year, because they are commonly used in the management of COPD. In a post hoc analysis, we explored a potential 3-way interaction among the main treatment effect, receiving LAAs, and a codiagnosis of asthma. We also stratified by previous receipt of spirometry, the recommended diagnostic test for COPD, 23 to determine whether more certainty about the diagnosis of COPD influenced the results. Propensity score calibration, using supplementary data from the Canadian Community Health Survey, was used to incorporate data on variables not available in the health administrative data (eAppendix in the Supplement). 24 We used an approach proposed by Schneeweiss, 25 as we have done previously, 14, 26 to determine the effect on our findings of potential COPD misclassification due to the case definition having an imperfect positive predictive value (eAppendix in the Supplement). Although we realized that it might be informative censoring that creates bias, to assess whether low adherence was affecting the results we conducted 2 further analyses, one in which individuals were censored at the time that they stopped using their initially prescribed medication and another in which they were censored 2 months before stopping (eAppendix in the Supplement).
Results
We Table 2) . Similarly lower risks were also observed for mortality and COPD hospitalizations analyzed separately. There was no significant difference in the risk of pneumonia or fracture hospitalization. Calibrating the propensity score using supplementary survey data on smoking, body mass index, and self-reported health had little effect (eTable 3 in the Supplement).
Differences in the association between LABA-ICS combination therapy vs LABAs alone and the primary outcome were observed in stratified analyses ( Table 3) . There was a statistically significant lower risk of the primary outcome among those with a codiagnosis of asthma (HR, 0.84; 95% CI, 0.77-0.91), those not receiving LAAs (HR, 0.79; 95% CI, 0.73-0.86), and those who had not received spirometry (HR, 0.87; 95% CI, 0.81-0.93). When a 3-way interaction among treatment, LAA use, and codiagnosis of asthma was explored, the interaction term was not significant (P = .31), but stratified analyses were conducted for exploratory purposes. Among individuals who did not have asthma and who were not receiving LAAs, new users of LABA-ICS combination therapy were at a significantly lower risk of the primary outcome compared with new users of LABAs alone (HR, 0.83; 95% CI, 0.75-0.92). Misclassification of COPD diagnosis could explain the significant association between medication groups and the primary outcome. However, only in extreme and unlikely scenarios would the results in those with asthma or without asthma not receiving LAAs be negated (eTable 4 in the Supplement).
When individuals were censored when they stopped using their initially prescribed medication, the HR of the primary outcomes was 0.94 (95% CI, 0.88-1.00), and when they were censored 2 months prior to when they stopped using their initially prescribed medication, it was 0.96 (95% CI, 0.90-1.03).
Discussion
We conducted a population-based study in adults aged 66 years or older with COPD and observed that new use of LABA-ICS combination therapy was associated with a modest but statistically significant lower risk of the composite outcome of death or COPD hospitalization compared with new use of LABAs alone and a more pronounced lower risk in subgroups of individuals with asthma and who were not receiving LAAs. To the best of our knowledge, this is the first large, real-world population study to compare LABAs and LABA-ICS combination therapy. c Continuity of care measured using the Bice method. The index ranges from 0 (each visit involves a different clinician than all other visits) to 1 (all visits were billed by a single clinician), where higher scores represent greater continuity. 
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ICSs and outcomes helps clarify the management of patients with COPD and asthma, as many studies of COPD medications have excluded people with asthma and vice versa. In addition, practice guidelines for COPD recommend that LABAs be considered first-line treatment while asthma guidelines warn against use of LABAs without ICSs. Our findings also offer insight into the optimal treatment of COPD patients without asthma-those who would not be considered especially corticosteroid responsive. In this subgroup, those who did not have asthma who were not receiving LAAs and who received LABAs and ICSs had a lower risk of the composite outcome of a magnitude similar to people with asthma. People without asthma who received LAAs did not have an association with better outcome, perhaps because the gains conferred by LAAs reduced the incremental benefit of LABA-ICS therapy or because in general they had more severe disease, which made them less responsive to medications. Previous studies comparing triple therapy with LABAs, ICSs, and LAAs and dual therapy with LABAs and LAAs have not been of sufficient quality to draw conclusions. 30 Our study is consistent with a recent systematic review and meta-analysis of RCTs that found that people taking combination LABA-ICS therapy had non-statistically significant lower ing a population with more outcomes, thus allowing results to reach statistical significance. It also includes and is generalizable to patients excluded from many of the RCTs in the review. In addition, some RCTs included volunteers who could have been receiving at least 1 of the medications before and who, because they agreed to take it again, were more likely to tolerate it and have favorable outcomes.
14 Our study is also consistent with a systematic review of RCTs that did not observe a higher occurrence of fractures among LABA-ICS users compared with users of LABAs alone. 8 It is not consistent with a systematic review of RCTs that observed an increased risk of pneumonia among combination LABA-ICS users. 7 Differences between observational studies and RCTs, notably our inclusion of frailer patients who were more likely to have risk factors for pneumonia hospitalization that overshadowed the risks of these medications, may explain this discrepancy. One observational study comparing ICSs with no ICSs that included frailer patients found pneumonia to be increased among the former. 31 There are many differences in study design that might explain why its results differed from ours (eAppendix in the Supplement). Our study had limitations. Unlike RCTs, observational study designs are susceptible to unmeasured confounding. Through the inclusion of multiple prognostic variables, and considering others through propensity score calibration, we strived to ensure that we accounted for all possible confounders. However, it is possible that there were residual differences between the groups.
Using health administrative data to identify people with COPD might have also led to misclassification of individuals with COPD. A plausible scenario that could have explained our overall results is that, due to an imperfect positive predictive value of our case definition, all the patients potentially misclassified as having COPD when they did not were in the LABA-ICS combination group and had a 20% decrease in risk of the primary outcome, perhaps because they truly had asthma. However, these patients would have had to have a 50% decreased risk of the primary outcome in those with asthma and a 40% decrease in those without asthma not receiving LAAs to explain the results-scenarios that we believe highly unlikely. It was also possible that due to an imperfect negative predictive value, there were people misclassified as not having COPD who were not included in our study when they should have been. Thus, while our findings likely apply to the majority of people with COPD, they might not apply to all.
In addition, as reflective of real life, adherence to medication was at the same low level as found in previous studies 14, 32 (eTable 5 in the Supplement). We considered but rejected conducting a time-on-treatment sensitivity analysis because people receiving LABAs often stepped up to LABAs and ICSs but not vice versa. As a result, people in the LABA-ICS group would be more likely to have advanced disease and to do worse. By using only new users, we were able to create comparable groups and follow them up in an intention-to-treat manner, taking medication changes that commonly occur in the community into consideration. More people in the LABA group were receiving LABAs alone-at least until they stepped up to LABAs and ICSsand more people in the LABA-ICS group were receiving LABAs and ICSs (eTable 5 in the Supplement). Thus, realworld conditions, specifically crossover, attenuated the groups' differences, producing conservative results that likely caused us to underestimate the incremental benefit of LABAs and ICSs over LABAs alone. When we censored people at or before the point when they stopped using the initially prescribed medication, the results were similar. The strengths of our study include its population, realworld relevance, and power to examine the relative effects of LABAs compared with LABAs and ICSs in various subgroups.
Conclusions
Among older adults with COPD, particularly those with asthma and those not receiving an LAA, newly prescribed LABA-ICS combination therapy, compared with newly prescribed LABAs alone, was associated with a significantly lower risk of the composite outcome of death or COPD hospitalization. These findings should be confirmed in RCTs.
